0001570562-24-000085.txt : 20240514
0001570562-24-000085.hdr.sgml : 20240514
20240514205601
ACCESSION NUMBER: 0001570562-24-000085
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240510
FILED AS OF DATE: 20240514
DATE AS OF CHANGE: 20240514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Avelar Rui
CENTRAL INDEX KEY: 0001432063
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38381
FILM NUMBER: 24946736
MAIL ADDRESS:
STREET 1: 1618 STATION STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6A 1B6
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evolus, Inc.
CENTRAL INDEX KEY: 0001570562
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461385614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 520 NEWPORT CENTER DRIVE
STREET 2: SUITE 1200
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
BUSINESS PHONE: (949) 284-4555
MAIL ADDRESS:
STREET 1: 520 NEWPORT CENTER DRIVE
STREET 2: SUITE 1200
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
4
1
wk-form4_1715734552.xml
FORM 4
X0508
4
2024-05-10
0
0001570562
Evolus, Inc.
EOLS
0001432063
Avelar Rui
520 NEWPORT CENTER DR.
SUITE 1200
NEWPORT BEACH
CA
92660
0
1
0
0
See Remarks
0
Common Stock
2024-05-10
4
S
0
3441
12.7174
D
368847
D
The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The shares were sold in multiple trades at prices ranging from $12.51 to $13.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Chief Medical Officer & Head of Research and Development
/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
2024-05-14